Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke
Yu Fu(AVEO Oncology (United States)), Dongsheng Fan(King University), Chuanling Li(Chinese Academy of Tropical Agricultural Sciences), Xue Xia(Capital Medical University), Fei Yi(Jiangxi Pingxiang People's Hospital), Xueshuang Dong(Daqing Oilfield General Hospital), Yun Ling(Zhejiang Chinese Medical University), Cunju Guo(Liaocheng People's Hospital), Shugen Han(Harbin Medical University), Xin Sun(Jilin University), Rong Chen(Shanghai Jiao Tong University), Bo Liu(Shandong Tumor Hospital), Shunwei Zhu(Simcere Pharmaceutical (China)), Zhimin Wang(Chinese University of Hong Kong), Yan Wei(Harrison International Peace Hospital), Qian Deng, Xue Tian(Tianjin University of Science and Technology), Aiqin Dong(Cangzhou Central Hospital), Shuya Li(Capital Medical University), Guoqiang Wen(Hainan General Hospital), Anxin Wang(Beijing Tian Tan Hospital), Jinliang Yao, Xueying Shi(Anqing City Hospital), Shibao Yang, Jinsheng Ren(Simcere Pharmaceutical (China)), Renhong Tang(Nanyang Technological University), Xiaofei Feng(Tongji University), Yi Sui(Peking University)
Cited by 97
Related Papers
Stroke in China: advances and challenges in epidemiology, prevention, and management
|The Lancet Neurology|2019|1.6k
Estimated Burden of Stroke in China in 2020
|JAMA Network Open|2023|595
China stroke surveillance report 2021
|Military Medical Research|2023|554
Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing
|Genome Medicine|2019|537
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415